PARACETAMOL

Informació principal

  • Denominació comercial:
  • PARACETAMOL SERRACLINICS 10 mg/ml 12 bolsas 50 ml
  • Vía de administración:
  • Forma: Viales
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • PARACETAMOL SERRACLINICS 10 mg/ml 12 bolsas 50 ml
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 658488
  • última actualització:
  • 08-06-2018

Prospecte: composició, indicacions, interacció, posologia, embaràs, lactància, reaccions adverses

PARACETAMOL SERRACLINICS 10 mg/ml 12

bolsas 50 ml

paracetamol

Indicacions

Medicament que disminueix el dolor (ANALG

SIC) i la febre (ANTIPIR

TIC).

Consideracions

Aquest medicament ha de ser administrat per via intravenosa.

Aquest medicament ha de ser administrat per un metge o un altre professional sanitari amb experi

ncia.

Aquest medicament

s d'un sol

s; rebutgi qualsevol resta de medicament que pugui quedar a l'env

s una vegada utilitzat.

Avisi el seu metge si pateix o ha patit problemes de fetge.

Aquest medicament modifica l'acci

d'altres f

rmacs, NO prengui altres medicaments sense consultar

abans al seu metge o farmac

utic.

NO begui alcohol mentre duri el tractament, perqu

poden augmentar els efectes adversos.

Efectes adversos

Si vost

segueix la pauta indicada, no solen apar

ixer efectes adversos.

Posologia

Li administraran aquest medicament a un centre sanitari.

Administrar 1 injectable cada 8 hores.

VIA INTRAVENOSA.

27-2-2014

Paracetamol use during pregnancy

Paracetamol use during pregnancy

A new Danish study suggests a possible connection between mothers' use of paracetamol painkillers during pregnancy and the risk of developing disorders like ADHD (attention deficit hyperactivity disorder) in children.

Danish Medicines Agency

3-8-2012

Danish Pharmacovigilance Update, 21 June 2012

Danish Pharmacovigilance Update, 21 June 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Decrease in the number of intoxications and suicide attempts using drugs containing acetylsalicylic acid or paracetamol.

Danish Medicines Agency

10-4-2019


Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806

Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806

Paracetamol / pseudoephedrine: CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00002307/201806

Europe - EMA - European Medicines Agency

5-4-2019


Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806

Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806

Paracetamol/pseudoephedrine: List of nationally authorised medicinal products - PSUSA/00002307/201806

Europe - EMA - European Medicines Agency

26-3-2019


Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808

Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808

Paracetamol / tramadol: List of nationally authorised medicinal products - PSUSA/00002310/201808

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Opinion/decision on a Paediatric investigation plan (PIP): Ibuprofen,Paracetamol, decision type: , therapeutic area: , PIP number: P/0135/2018

Europe - EMA - European Medicines Agency

30-8-2018

Consultation: Referral of proposed amendment to the current Poisons Standard to the meeting of the ACMS, March 2019

Consultation: Referral of proposed amendment to the current Poisons Standard to the meeting of the ACMS, March 2019

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'. Closing date 31 October 2018

Therapeutic Goods Administration - Australia

30-8-2018

Modified release paracetamol

Modified release paracetamol

Advisory Committee on Medicines Scheduling to consider upscheduling of modified release paracetamol to 'Pharmacist Only'

Therapeutic Goods Administration - Australia